Monte Rosa Therapeutics Inc (GLUE)
EBITDA Growth
-523.95%
TTM · Period ending:
GLUE EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported-523.95%period ending
Latest reported-523.95%period ending
GLUE TTM EBITDA YoY % (-158.57% → -523.95%)
Year-over-year change
High-resolution chart · PNG
GLUE ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| -523.9493% | |
| -796.6505% | |
| 49.4154% | |
| 127.2577% | |
| 129.5158% | |
| 113.6262% | |
| 52.6811% | |
| 14.0958% | |
| -3.3748% | |
| -15.7224% | |
| -25.0955% | |
| -32.4075% | |
| -32.9152% | |
| -35.4939% | |
| -47.4315% | |
| -62.4235% | |
| -92.4686% | |
| -140.714% | |
| -158.5662% |